| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 20, 2004
Accepted on October 19, 2004
-catenin Is Involved in Insulin-Like Growth Factor 1-Mediated Transactivation of the Androgen Receptor
Department of Urology and Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305-5328
* To whom correspondence should be addressed. E-mail: zsun{at}stanford.edu.
The androgen-signaling pathway is important for the growth and progression of prostate cancer cells. The insulin growth factor 1 (IGF-I) and other polypeptide growth factors have been shown to be capable of induction of AR activation in the absence of, or at low levels of, ligand. It has been shown that IGF-I increases the cellular level of 
-catenin, an AR co-activator. In this study, we performed several experiments to test whether -catenin is involved in IGF-I induced AR-mediated transcription. We demonstrate that IGF-I enhances the expression of endogenous prostate specific antigen (PSA), an AR target gene, and elevates the level of cytoplasmic and nuclear -catenin in prostate cancer cells. Transfection of either wild-type or a constitutively active mutant of the IGF-I receptor (IGF-1R) augments AR-mediated transcription. An antisense construct of -catenin that decreases the cellular level of -catenin can reduce IGF-1R-mediated enhancement of AR activity. Moreover, using a pulse-chase experiment, we showed that IGF-I enhances the stability of -catenin in prostate cancer cells. Our findings delineate a novel pathway for IGF-I in modulating androgen signaling through -catenin.
-catenin •
IGF-1 •
prostate cancer
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  F. Yi, J. Sun, G. E. Lim, I. G. Fantus, P. L. Brubaker, and T. Jin Cross Talk between the Insulin and Wnt Signaling Pathways: Evidence from Intestinal Endocrine L Cells Endocrinology, May 1, 2008; 149(5): 2341 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fan, T. Yanase, H. Morinaga, T. Okabe, M. Nomura, H. Daitoku, A. Fukamizu, S. Kato, R. Takayanagi, and H. Nawata Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor J. Biol. Chem., March 9, 2007; 282(10): 7329 - 7338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Govoni, S. K. Lee, R. B. Chadwick, H. Yu, Y. Kasukawa, D. J. Baylink, and S. Mohan Whole genome microarray analysis of growth hormone-induced gene expression in bone: T-box3, a novel transcription factor, regulates osteoblast proliferation Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E128 - E136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know? Endocr. Rev., December 1, 2005; 26(7): 898 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fonte, J. Grenier, A. Trousson, A. Chauchereau, O. Lahuna, E.-E. Baulieu, M. Schumacher, and C. Massaad Involvement of {beta}-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells PNAS, October 4, 2005; 102(40): 14260 - 14265. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
